Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BMS, Roche to Collaborate in PI/II Trials of Combination Treatment for Melanoma
June 13, 2011
- 9 Companies Inaugurate Japan CSO Association on June 1
June 13, 2011
- Trisenox Launched in South Korea through BL&H: Nippon Shinyaku
June 13, 2011
- Sanofi Pasteur to Develop Single-antigen IPV in Japan
June 13, 2011
- Eisai's Achievements Most Conspicuous in FY2011 Settlement of Accounts: Nomura Securities
June 13, 2011
- IMUC Becomes 18th Licensee for POTELLIGENT Technology: BioWa
June 13, 2011
- Kyowa Hakko Bio Establishes Efficient Amino Acid Derivative Manufacturing Process
June 13, 2011
- Teijin: Bonalon, Onealfa Contribute to Growth in Sales
June 13, 2011
- DSP to Inaugurate Global Oncology Business Development Office
June 13, 2011
- NanoCarrier's Micelle Technology Moves Closer to Patent in Japan
June 13, 2011
- Meiji HD: Pharmaceuticals Segment's Sales Up 2.3%
June 13, 2011
- JPMA to Issue Serious Warning against MSD over PC Violations
June 13, 2011
- OPC-34712's Promise as New Antipsychotic Confirmed in PII: Otsuka
June 13, 2011
- Kyorin HD: Double-Digit Growth in Sales, Profits Driven by Kipres
June 6, 2011
- Chugai Applies for Pediatric Use, Dosage of CellCept
June 6, 2011
- Kaken: Operating Profits Up 20%
June 6, 2011
- BM Files for Breast Cancer for Paraplatin Based on Public Knowledge
June 6, 2011
- Mochida: Net Profits Down 46% due to Earthquake
June 6, 2011
- Korosho Designates Velaglucerase Alfa as Orphan Drug for Gaucher's Disease
June 6, 2011
- Kissei: Sales Up 3.6% Driven by Major Products Including Urief
June 6, 2011
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…